World J Oncol
World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website http://www.wjon.org

Letter to the Editor

Volume 10, Number 6, December 2019, pages 237-239


Midostaurin-Related Interstitial Lung Injury in FLT3+ Acute Myeloid Leukemia Post-Allogeneic Transplant

Poorva Vaidyaa, Tarek Khedrob, Bassam Yaghmourc, George Yaghmourb, d

aDepartment of Internal Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
bDivision of Hematology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
cDepartment of Pulmonary and Critical Care, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
dCorresponding Author: George Yaghmour, Division of Hematology, Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave, Los Angeles, CA 90033, USA

Manuscript submitted September 7, 2019, accepted October 7, 2019
Short title: Midostaurin-Related Lung Injury in FLT3+ AML
doi: https://doi.org/10.14740/wjon1232

To the Editor▴Top 

A mutation of the FLT3 receptor tyrosine kinase caused by an internal tandem duplication, FLT3-ITD, is the most frequent molecular anomaly found in 28-34% of cytogenetically normal acute myeloid leukemia (AML) patients, and confers a poor prognosis [1]. The drug midostaurin inhibits FLT3 cell signaling, thereby inducing apoptosis of leukemic cells. The agent shows great promise as a multi-targeted therapy in the treatment of a disease with historically dismal outcomes [2, 3]. Schlenk et al (2019) recently reported that although midostaurin as a continued single-agent maintenance therapy results in improved event-free survival (EFS) rates, its associated toxicities, particularly cardiac and pulmonary, need to be further elucidated [4]. One case of midostaurin-induced pneumonitis has previously been reported in an AML patient with FLT3 mutation prior to bone marrow transplant [5]. Three incidents of fatal pulmonary toxicity of unknown etiology were also reported in early studies of the drug [6]. The role of FLT3 inhibitors as post-transplant maintenance therapy is emerging. Here, we describe one case of a FLT3+ AML patient developing interstitial lung disease while on midostaurin therapy post-allogeneic stem cell transplant. To our knowledge, this is the first report of pulmonary toxicity post-allogeneic transplant. Here, we aim to further characterize midostaurin-induced interstitial lung disease and provide insight into its prevention and early detection.

A 66-year-old woman with no history of lung disease was diagnosed with AML. Bone marrow biopsy showed myelomonocytic leukemia. Molecular studies confirmed FLT3+ ITD mutation. No tyrosine kinase domain mutation was identified. She completed an induction therapy of 7 days of cytarabine infusion followed by 3 days of daunorubicin infusion (7 + 3) and entered complete remission. She then received two doses of high dose cytarabine, but soon relapsed. Bone marrow biopsy and molecular studies at the time showed FLT3+ ITD AML again. She was then started on salvage induction with cladribine, cytarabine, filgrastim and mitoxantrone (CLAG-M).

The safety of midostaurin combined with anthracycline plus cytarabine-based chemotherapy has been investigated thoroughly as a front-line therapy [2]. In a refractory setting, however, midostaurin was shown to have minimal efficacy in a Phase II trial as single agent [7]. Many patients in the trial showed significant blast count reductions, but none achieved complete remission. Our patient received their induction treatment before Food and Drug Administration (FDA) approval of midostaurin as a front-line therapy, not to mention the limited access to midostaurin of their initial treating physician. Thus, upon institutional approval, midostaurin was approved to be used off-label combined with CLAG-M. It was thought that adding an FLT3+ targeted therapy agent would be beneficial. Per the FDA label of the approved front-line therapy, midostaurin was dosed at 50 mg twice daily from day 8 to day 21. A subsequent repeat bone marrow biopsy showed complete molecular remission.

Eleven months after initial diagnosis, our patient received a 5/10 haploidentical allogeneic transplant. Post-transplant cyclophosphamide (PTCy) was administered per Hopkins’ haploidentical protocol as prophylaxis for graft-versus-host disease (GVHD). She tolerated the transplant process and continued midostaurin therapy at 25 mg PO daily.

Seven months post-transplant, the patient was hospitalized for worsening shortness of breath and worsening hypoxemia without fevers or leukocytosis. Blood cultures were negative and induced sputum grew normal respiratory flora. Infectious workup was also negative for Pneumocystis jirovecii, aspergillus, Epstein-Barr virus, cytomegalovirus, and a respiratory viral panel. Pulmonary function test (PFT) showed no evidence of pulmonary obstruction. At the time of admission, the patient was taking rivaroxaban for pulmonary embolism, but entilation/perfusion (V/Q) scan showed no evidence of new embolus. High-resolution computed tomography (HRCT) of the chest showed bilateral smooth interlobular septal thickening with scattered ground glass opacities and pulmonary interstitial edema (Fig. 1a). Brain natriuretic peptide (BNP) was 140 pg/mL. Transthoracic echocardiogram (TTE) showed an ejection fraction of 61% and right ventricle systolic pressure elevated to 55 mm Hg. A bubble study did not show evidence of shunting.

Figure 1.
Click for large image
Figure 1. (a) HRCT of thorax demonstrating bilateral pleural effusions, scattered ground glass opacities, and interlobular septal thickening, and (b) HRCT showing resolution of ground glass opacities and pulmonary edema after midostaurin cessation. HRCT: high-resolution computed tomography.

Midostaurin was stopped due to concern of drug-related interstitial lung disease, and subsequently, the patient’s symptoms started improving. Biopsy could not be conducted due to a high risk of bleeding. The patient was diuresed with furosemide and a pulmonary consult recommended starting the patient on prednisone. Repeat HRCT chest 3 months later showed interval resolution of pulmonary edema as well as decrease in lower lobe ground glass opacities (Fig. 1b). Repeat echocardiogram showed improvement in right ventricular systolic pressure to 45 mm Hg. During the course of the treatment, the patient developed pulmonary hypertension with right heart strain that was improved on diuresis with furosemide. She was started on pulmonary hypertension medications sildenafil and macitentan. The respiratory symptoms continued improving, and the steroids were slowly tapered off. The patient’s C-reactive protein (CRP) peaked to 70 mg/dL and normalized at 2.3 mg/dL, and lactate dehydrogenase (LDH) reached a level of 300 U/L and normalized at 199 U/L. The patient continued to be in complete remission, maintaining full chimerism 19 months post-transplant.

Drug-induced lung disease, often a diagnosis of exclusion, is associated with both antineoplastic and non-neoplastic agents. The most common HRCT findings have been described as ground-glass opacities, which are often found in a diffuse pattern in toxicities associated with antineoplastic agents [8, 9]. In our patient, we observed worsening respiratory status with HRCT findings of interlobular septal thickening and scattered ground glass opacities approximately 7 months after allogeneic stem cell transplant and at a midostaurin dose of 25 mg daily. Cessation of midostaurin and treatment with steroids resulted in significant improvement in both clinical symptoms and radiologic findings within 3 months. To our knowledge, although midostaurin has previously been implicated in pulmonary toxicity, this is the first described case of pulmonary toxicity post-allogeneic transplant [5, 6]. Of note, our patient also received PTCy as prophylaxis against GVHD. As cyclophosphamide is also associated with pulmonary toxicity [8], it is possible that its combination with midostaurin only increased the chances of pulmonary complications. Future directions in understanding the risk of interstitial lung injury associated with midostaurin involve identifying the time after transplant that toxicity is likely to occur, whether toxicity is dose dependent, whether the drug can be safely re-introduced after resolution of symptoms and whether its combination with other agents is feasible and safe.

Acknowledgments

None to declare.

Financial Disclosure

George Yaghmour disclose: Pharma bureau speaker for Jazz, Takeda, and Astella Pharmaceutical Company. There is no declaration for others, and no funding was provided.

Conflict of Interest

The authors do not have any conflict of interest.

Informed Consent

Not applicable.

Author Contributions

PV, TK, BY, and GY performed the research and wrote the paper.


References▴Top 
  1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152.
    doi pubmed
  2. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454-464.
    doi pubmed
  3. National Cancer Institute Surveillance Epidemiology and End Results Program. Acute Myeloid Leukemia. 2019.
  4. Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840-851.
    doi pubmed
  5. Lee B, Onofrei CD, Sheski F. The culprit midostaurin in a case of drug-induced pneumonitis. Drug Induc. Case Reports. 2018:A6647.
  6. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54-60.
    doi pubmed
  7. Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010;28(28):4339-4345.
    doi pubmed
  8. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Muller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol. 2002;57(4):292-299.
    doi pubmed
  9. Akira M, Ishikawa H, Yamamoto S. Drug-induced pneumonitis: thin-section CT findings in 60 patients. Radiology. 2002;224(3):852-860.
    doi pubmed


This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


World Journal of Oncology is published by Elmer Press Inc.

 

Browse  Journals  

     

Journal of clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 

 

 

 

World Journal of Oncology, bimonthly, ISSN 1920-4531 (print), 1920-454X (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.wjon.org   editorial contact: editor@wjon.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.